deferoxamine has been researched along with Liver Dysfunction in 60 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery, and reduced brain edema, intracranial pressure, and lung injury in pigs with acute hepatic ischemia (AHI)." | 7.78 | Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. ( Arkadopoulos, N; Degiannis, D; Demonakou, M; Kaklamanis, L; Kostopanagiotou, G; Siasiakou, S; Smyrniotis, V; Vlahakos, D, 2012) |
| "Cadmium (Cd) is a type of high-risk heavy metal that can damage organs such as the liver, but its mechanism is not yet clear." | 5.72 | Cadmium induces liver dysfunction and ferroptosis through the endoplasmic stress-ferritinophagy axis. ( Fan, G; Feng, L; Fu, Y; Hao, H; He, Y; He, Z; Hu, X; Liu, Z; Shen, P; Wang, Y; Wu, J; Zhang, N; Zhu, K, 2022) |
| "We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery, and reduced brain edema, intracranial pressure, and lung injury in pigs with acute hepatic ischemia (AHI)." | 3.78 | Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. ( Arkadopoulos, N; Degiannis, D; Demonakou, M; Kaklamanis, L; Kostopanagiotou, G; Siasiakou, S; Smyrniotis, V; Vlahakos, D, 2012) |
| " It is also the second case report of a Pearson patient suffering from severe iron overload and liver disease that responded to therapy with deferoxamine." | 3.74 | Pearson syndrome in an infant heterozygous for C282Y allele of HFE gene. ( Augoustides-Savvopoulou, P; Farmaki, E; Karatza, E; Kefala-Agoropoulou, K; Lazaridou, A; Roilides, E; Tsantali, H; Tsiouris, J, 2007) |
| " A complex synthesized from GA and soybean lecithin (SL-GAC), significantly improved bioavailability of GA and pharmacological activities." | 1.91 | Amelioration effects of the soybean lecithin-gallic acid complex on iron-overload-induced oxidative stress and liver damage in C57BL/6J mice. ( Cui, W; Dai, W; Fang, F; Gao, Y; Wu, C; Yan, F; Zhang, W, 2023) |
| "Cadmium (Cd) is a type of high-risk heavy metal that can damage organs such as the liver, but its mechanism is not yet clear." | 1.72 | Cadmium induces liver dysfunction and ferroptosis through the endoplasmic stress-ferritinophagy axis. ( Fan, G; Feng, L; Fu, Y; Hao, H; He, Y; He, Z; Hu, X; Liu, Z; Shen, P; Wang, Y; Wu, J; Zhang, N; Zhu, K, 2022) |
| "Diabetes insipidus is a rare disorder in pregnant women, predating pregnancy or appearing for the first time during gestation." | 1.36 | Recurrent pregnancy-induced diabetes insipidus in a woman with hemochromatosis. ( Kobielusz-Gembala, I; Krysiak, R; Okopien, B, 2010) |
| " DFO at a dosing level equivalent to 10-fold of that of DXR was useful to obtain protective effects." | 1.31 | The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. ( Al-Rikabi, AC; Najjar, TA; Saad, SY, 2001) |
| "To describe the burden of thalassemia major and its treatment, in terms of prevalence of iron-overload-related complications, direct and indirect costs, and the patient's physical and social well-being." | 1.31 | Impact of thalassemia major on patients and their families. ( Arana, A; Caro, JJ; Eleftheriou, A; Green, TC; Huybrechts, K; Wait, S; Ward, A, 2002) |
| "Insulin-dependent diabetes mellitus (IDDM) is a frequent complication in patients with beta-thalassaemia major." | 1.29 | Diabetes mellitus in children suffering from beta-thalassaemia. ( al-Fawaz, I; al-Swailem, A; el-Hazmi, MA; Warsey, AS, 1994) |
| "Pretreatment with deferoxamine resulted in a significant decrease in lung leak as compared to animals pretreated with vehicle prior to I/R (DES-I/R = 0." | 1.29 | Desferal attenuates TNF release following hepatic ischemia/reperfusion. ( Campbell, DA; Colletti, LM; Remick, DG, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 30 (50.00) | 18.7374 |
| 1990's | 10 (16.67) | 18.2507 |
| 2000's | 10 (16.67) | 29.6817 |
| 2010's | 8 (13.33) | 24.3611 |
| 2020's | 2 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| He, Z | 1 |
| Shen, P | 1 |
| Feng, L | 1 |
| Hao, H | 1 |
| He, Y | 1 |
| Fan, G | 1 |
| Liu, Z | 1 |
| Zhu, K | 1 |
| Wang, Y | 1 |
| Zhang, N | 1 |
| Hu, X | 1 |
| Fu, Y | 1 |
| Wu, J | 1 |
| Wu, C | 1 |
| Zhang, W | 1 |
| Yan, F | 1 |
| Dai, W | 1 |
| Fang, F | 1 |
| Gao, Y | 1 |
| Cui, W | 1 |
| Abdelgelil, NH | 1 |
| Abdellatif, MZM | 1 |
| Abdel-Hafeez, EH | 1 |
| Belal, US | 1 |
| Mohamed, RM | 1 |
| Abdel-Razik, AH | 1 |
| Hassanin, KMA | 1 |
| Abdel-Wahab, A | 1 |
| Hernández-Sánchez, A | 1 |
| Tejada-González, P | 1 |
| Arteta-Jiménez, M | 1 |
| Niu, X | 1 |
| Huang, WH | 1 |
| De Boer, B | 1 |
| Delriviere, L | 1 |
| Mou, LJ | 1 |
| Jeffrey, GP | 1 |
| Cermanova, J | 1 |
| Kadova, Z | 1 |
| Dolezelova, E | 1 |
| Zagorova, M | 1 |
| Safka, V | 1 |
| Hroch, M | 1 |
| Laho, T | 1 |
| Holeckova, M | 1 |
| Mokry, J | 1 |
| Kovarikova, P | 1 |
| Bures, J | 1 |
| Sterba, M | 1 |
| Micuda, S | 1 |
| Trogadas, G | 1 |
| Mastoraki, A | 1 |
| Nastos, C | 1 |
| Kondi-Pafiti, A | 1 |
| Kostopanagiotou, G | 2 |
| Smyrniotis, V | 2 |
| Arkadopoulos, N | 2 |
| Tauchenová, L | 1 |
| Křížová, B | 1 |
| Kubánek, M | 1 |
| Fraňková, S | 1 |
| Melenovský, V | 1 |
| Tintěra, J | 1 |
| Kautznerová, D | 1 |
| Malušková, J | 1 |
| Jirsa, M | 1 |
| Kautzner, J | 1 |
| Krysiak, R | 1 |
| Kobielusz-Gembala, I | 1 |
| Okopien, B | 1 |
| Vlahakos, D | 1 |
| Siasiakou, S | 1 |
| Kaklamanis, L | 1 |
| Degiannis, D | 1 |
| Demonakou, M | 1 |
| Jensen, PD | 1 |
| Jensen, FT | 1 |
| Christensen, T | 1 |
| Nielsen, JL | 1 |
| Ellegaard, J | 1 |
| DARNAUD, C | 1 |
| DENARD, Y | 1 |
| VOISIN, R | 1 |
| LEMOZY, J | 1 |
| SCHNACK, H | 2 |
| WEWALKA, F | 2 |
| WALSH, JR | 1 |
| MASS, RE | 1 |
| SMITH, FW | 1 |
| LANGE, V | 1 |
| RISSEL, E | 2 |
| Zhuang, J | 1 |
| Wang, Z | 1 |
| Liu, J | 1 |
| Gou, L | 1 |
| Wood, DM | 1 |
| Thomson, AH | 1 |
| Lawes, M | 1 |
| Jones, AL | 1 |
| Dargan, PI | 1 |
| Gancz, AY | 1 |
| Wellehan, JF | 1 |
| Boutette, J | 1 |
| Malka, S | 1 |
| Lee, SE | 1 |
| Smith, DA | 1 |
| Taylor, M | 1 |
| Kefala-Agoropoulou, K | 1 |
| Roilides, E | 1 |
| Lazaridou, A | 1 |
| Karatza, E | 1 |
| Farmaki, E | 1 |
| Tsantali, H | 1 |
| Augoustides-Savvopoulou, P | 1 |
| Tsiouris, J | 1 |
| Brusa, L | 1 |
| De Filippi, PG | 1 |
| Cravario, A | 1 |
| Scuro, LA | 2 |
| Dobrilla, G | 2 |
| Gibertini, P | 1 |
| Rocchi, E | 2 |
| Cassanelli, M | 2 |
| Pietrangelo, A | 1 |
| Ventura, E | 2 |
| Ley, TJ | 1 |
| Griffith, P | 1 |
| Nienhuis, AW | 1 |
| Locasciulli, A | 1 |
| Monguzzi, W | 1 |
| Tornotti, G | 1 |
| Bianco, P | 1 |
| Masera, G | 1 |
| el-Hazmi, MA | 1 |
| al-Swailem, A | 2 |
| al-Fawaz, I | 1 |
| Warsey, AS | 1 |
| Gabutti, V | 2 |
| Borgna-Pignatti, C | 2 |
| Colletti, LM | 1 |
| Remick, DG | 1 |
| Campbell, DA | 1 |
| Giardini, C | 1 |
| La Nasa, G | 1 |
| Contu, L | 1 |
| Galimberti, M | 1 |
| Polchi, P | 1 |
| Angelucci, E | 1 |
| Baronciani, D | 1 |
| Barbanti, I | 1 |
| Muretto, P | 1 |
| Lucarelli, G | 1 |
| Zurlo, MG | 1 |
| DeStefano, P | 1 |
| Boffa, C | 1 |
| DeSanctis, V | 1 |
| DiPalma, A | 1 |
| DiGregorio, L | 1 |
| Melevendi, C | 1 |
| Piga, A | 2 |
| Sabato, V | 1 |
| Omara, FO | 1 |
| Blakley, BR | 1 |
| Bauer, C | 1 |
| Marzi, I | 1 |
| Larsen, R | 1 |
| Prati, D | 1 |
| Olivieri, NF | 1 |
| Saad, SY | 1 |
| Najjar, TA | 1 |
| Al-Rikabi, AC | 1 |
| Hasegawa, T | 1 |
| Nakano, M | 1 |
| Hashimoto, T | 1 |
| Hiraishi, K | 1 |
| Suzuki, K | 1 |
| Kuwano, H | 1 |
| Caro, JJ | 1 |
| Ward, A | 1 |
| Green, TC | 1 |
| Huybrechts, K | 1 |
| Arana, A | 1 |
| Wait, S | 1 |
| Eleftheriou, A | 1 |
| Cartei, G | 4 |
| Barbui, T | 2 |
| Cazzavillan, M | 2 |
| Chisesi, T | 2 |
| Dini, E | 2 |
| Strohmeyer, G | 1 |
| Pearson, HA | 1 |
| O'Brien, RT | 1 |
| Sorbie, J | 1 |
| Valberg, LS | 1 |
| Corbett, WE | 1 |
| Ludwig, J | 1 |
| Borghi, A | 1 |
| Paolillo, F | 1 |
| Pradelli, M | 1 |
| Pellizzardi, S | 1 |
| Vezzosi, A | 1 |
| Gallo, E | 1 |
| Baccarani Contri, M | 1 |
| Perrimond, H | 1 |
| Chagnon, C | 1 |
| Moulanier, I | 1 |
| Michel, G | 1 |
| Guidicelli, H | 1 |
| Bernard, PJ | 1 |
| Triadou, P | 1 |
| Regnat-Lusinchi, A | 1 |
| Girot, R | 1 |
| Sacchetti, L | 1 |
| Sandri, A | 1 |
| Biginelli, M | 1 |
| Saracco, P | 1 |
| Ferri, M | 1 |
| De Matteis, F | 1 |
| De Sanctis, V | 1 |
| D'Ascola, G | 1 |
| Wonke, B | 1 |
| Williams, JW | 1 |
| Vera, SR | 1 |
| Peters, TG | 1 |
| Luther, RW | 1 |
| Bhattacharya, S | 1 |
| Spears, H | 1 |
| Graham, A | 1 |
| Pitcock, JA | 1 |
| Crawford, AJ | 1 |
| Palmieri, GM | 1 |
| Festa, RS | 1 |
| Battista, R | 1 |
| Stromeyer, G | 1 |
| Stacher, A | 1 |
| Turnbull, A | 1 |
| Haneke, E | 1 |
| Schwartze, G | 1 |
| Schmidt, UJ | 1 |
| Kranz, D | 1 |
| Brüschke, G | 1 |
| Kalbe, I | 1 |
| Rürup, B | 1 |
| Barry, M | 1 |
| Sherlock, S | 1 |
| Scandellari, C | 1 |
| Bosello, O | 1 |
| Cavallini, G | 1 |
| Lo Cascio, V | 1 |
| Heilmeyer, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations[NCT04333550] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2020-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for deferoxamine and Liver Dysfunction
| Article | Year |
|---|---|
Aluminium in parenteral nutrition: a systematic review.
Topics: Aluminum; Alzheimer Disease; Bone Diseases, Metabolic; Deferoxamine; Dyslipidemias; Humans; Iron; Ke | 2013 |
Transfusion haemosiderosis and chelation therapy.
Topics: Adolescent; Adult; Ascorbic Acid; Blood Transfusion; Cardiomyopathies; Deferoxamine; Dose-Response R | 1982 |
Clinical manifestations and therapy of transfusional haemosiderosis.
Topics: Adolescent; Adult; Chelation Therapy; Deferoxamine; Endocrine System Diseases; Female; Heart Disease | 1994 |
Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major.
Topics: Anemia, Hemolytic; beta-Thalassemia; Blood Group Incompatibility; Blood Transfusion; Cardiovascular | 2000 |
[Iron storage disorders].
Topics: Arrhythmias, Cardiac; Bloodletting; Deferoxamine; Diabetes Complications; Ferritins; Follicle Stimul | 1978 |
Modern management of thalassemia.
Topics: Adolescent; Arrhythmias, Cardiac; Ascorbic Acid; Blood Transfusion; Child; Cholelithiasis; Deferoxam | 1985 |
[Diseases caused by iron metabolism disorders and their therapy].
Topics: Adult; Anemia, Hypochromic; Anti-Glomerular Basement Membrane Disease; Bloodletting; Deferoxamine; D | 1969 |
Iron metabolism in the porphyrias.
Topics: Alcohol Drinking; Amino Acids; Anemia, Hemolytic; Bloodletting; Bone Marrow; Bone Marrow Diseases; D | 1971 |
1 trial available for deferoxamine and Liver Dysfunction
| Article | Year |
|---|---|
Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias.
Topics: Adult; Aged; Anemia; Chelation Therapy; Deferoxamine; Female; Humans; Iron; Iron Chelating Agents; I | 2003 |
51 other studies available for deferoxamine and Liver Dysfunction
| Article | Year |
|---|---|
Cadmium induces liver dysfunction and ferroptosis through the endoplasmic stress-ferritinophagy axis.
Topics: Autophagy; Cadmium; Chloroquine; Deferoxamine; Endoplasmic Reticulum Stress; Ferritins; Ferroptosis; | 2022 |
Amelioration effects of the soybean lecithin-gallic acid complex on iron-overload-induced oxidative stress and liver damage in C57BL/6J mice.
Topics: Animals; Antioxidants; Deferoxamine; Gallic Acid; Glycine max; Iron; Iron Overload; Lecithins; Lipid | 2023 |
Effects of iron chelating agent on Schistosoma mansoni infected murine model.
Topics: Animals; Deferoxamine; Disease Models, Animal; Granuloma; Iron Chelating Agents; Liver Cirrhosis; Li | 2019 |
Iron-induced oxidative rat liver injury after non-heart-beating warm ischemia is mediated by tumor necrosis factor α and prevented by deferoxamine.
Topics: Adenosine; Allopurinol; Animals; Aspartate Aminotransferases; Bile; Deferoxamine; Disease Models, An | 2014 |
Deferoxamine but not dexrazoxane alleviates liver injury induced by endotoxemia in rats.
Topics: Animals; Deferoxamine; Dexrazoxane; Endotoxemia; Iron Chelating Agents; Liver Diseases; Male; Rats; | 2014 |
Comparative Effects of Ischemic Preconditioning and Iron Chelation in Hepatectomy.
Topics: Animals; Deferoxamine; Female; Hepatectomy; Iron Chelating Agents; Ischemic Preconditioning; Liver D | 2015 |
Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone.
Topics: Cardiomyopathies; Deferiprone; Deferoxamine; Ferritins; Heart Failure; Hemochromatosis; Hemochromato | 2016 |
Recurrent pregnancy-induced diabetes insipidus in a woman with hemochromatosis.
Topics: Adult; Biopsy, Needle; Cystinyl Aminopeptidase; Deferoxamine; Diabetes Insipidus; Female; Hemochroma | 2010 |
Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs.
Topics: Acute Disease; Acute Kidney Injury; Animals; Apoptosis; Deferoxamine; Female; Interleukin-6; Ischemi | 2012 |
[DESFERRIOXAMINE IN THE TREATMENT OF HEMOCHROMATOSIS].
Topics: Chelating Agents; Deferoxamine; Diuresis; Gastric Mucosa; Hemochromatosis; Hepatomegaly; Humans; Liv | 1964 |
[RESULTS OF A TEST FOR DEMONSTRATION OF INCREASED IRON DEPOSITION IN THE BODY OF LIVER DISEASES].
Topics: Deferoxamine; Humans; Iron; Liver Diseases | 1964 |
IRON CHELATION WITH DEFEROXAMINE IN HEPATIC DISEASE.
Topics: Ammonium Chloride; Biological Transport; Deferoxamine; Fluids and Secretions; Gene Expression Regula | 1965 |
[DESFERRIOXAMINE THERAPY IN LIVER DISEASES].
Topics: Deferoxamine; Drug Therapy; Hemochromatosis; Humans; Iron; Liver Diseases | 1964 |
[ON THE TREATMENT OF HEPATIC SIDEROSIS].
Topics: Deferoxamine; Drug Therapy; Hemochromatosis; Hepatolenticular Degeneration; Humans; Liver Diseases; | 1964 |
[Putative mechanism of experimental immunological liver injury and influence of iron low-load on the injury in rat].
Topics: Animals; Deferoxamine; Disease Models, Animal; Iron; Iron Deficiencies; Lipid Peroxidation; Lipopoly | 2004 |
Hepatocellular damage following therapeutic intravenous iron sucrose infusion in a child.
Topics: Anemia, Iron-Deficiency; Chemical and Drug Induced Liver Injury; Child, Preschool; Deferoxamine; Fer | 2005 |
Diabetes mellitus concurrent with hepatic haemosiderosis in two macaws (Ara severa, Ara militaris).
Topics: Animals; Deferoxamine; Diabetes Complications; Female; Hemosiderosis; Insulin; Liver Diseases; Male; | 2007 |
Pearson syndrome in an infant heterozygous for C282Y allele of HFE gene.
Topics: Anemia, Sideroblastic; Deferoxamine; Fatal Outcome; Female; Hemochromatosis; Hemochromatosis Protein | 2007 |
[Effect of deferoxamine on urinary excretion of iron in chronic non-hemochromatosic liver diseases].
Topics: Adolescent; Adult; Aged; Deferoxamine; Female; Humans; Iron; Liver Diseases; Male; Middle Aged | 1967 |
Siderosis, haemolysis or hepatonecrosis in increasing post-desferrioxamine sideruria in acute viral hepatitis?
Topics: Deferoxamine; Hemolysis; Hepatitis A; Humans; Iron; Liver Diseases; Necrosis; Siderosis | 1967 |
Porphyria cutanea tarda in beta-thalassemia trait carriers.
Topics: Adult; Deferoxamine; Heterozygote; Humans; Liver Diseases; Male; Middle Aged; Porphyrias; Skin Disea | 1984 |
Hepatitis C virus infection and liver disease in children with thalassemia.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Combined Modality T | 1993 |
Diabetes mellitus in children suffering from beta-thalassaemia.
Topics: Adolescent; Age Factors; beta-Thalassemia; Blood Glucose; Child; Deferoxamine; Diabetes Mellitus, Ty | 1994 |
Desferal attenuates TNF release following hepatic ischemia/reperfusion.
Topics: Alanine Transaminase; Animals; Deferoxamine; Disease Models, Animal; Liver; Liver Diseases; Lung Dis | 1994 |
Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
Topics: Adolescent; beta-Thalassemia; Chelation Therapy; Combined Modality Therapy; Deferoxamine; Ferritins; | 1993 |
Outcome of thalassemia treated with conventional therapy.
Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Cardiovascular Diseases; Cause of Death; Chelation | 1993 |
Vitamin E is protective against iron toxicity and iron-induced hepatic vitamin E depletion in mice.
Topics: Animals; Chemical and Drug Induced Liver Injury; Deferoxamine; Diet; Iron; Liver; Liver Diseases; Ma | 1993 |
[Deferoxamine-conjugated hydroxyethyl starch reduces reperfusion injury to the liver following hemorrhagic shock].
Topics: Animals; Antioxidants; Blood Volume; Cell Adhesion; Chelating Agents; Deferoxamine; Female; Glutathi | 1997 |
Progression of iron overload in sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Biopsy, Needle; Child; Child, Preschool; Cohort Studies; Def | 2001 |
The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats.
Topics: Analysis of Variance; Animals; Chelating Agents; Chemical and Drug Induced Liver Injury; Deferoxamin | 2001 |
Sinusoidal endothelial cell injury by superoxide anion and iron in the Propionibacterium acnes-pretreated and lipopolysaccharide-stimulated rat liver.
Topics: Animals; Deferoxamine; Endothelium, Vascular; Gram-Positive Bacterial Infections; Iron; Iron Chelati | 2001 |
Impact of thalassemia major on patients and their families.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Cost of Illness; Deferoxamine; Diabetes Complications; E | 2002 |
Desferrioxamine B: reversible side effects of high daily doses.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Ch | 1975 |
The management of thalassemia major.
Topics: Adolescent; Adult; Blood Transfusion; Chelating Agents; Child; Child, Preschool; Deferoxamine; Diet | 1975 |
Serum ferritin, cobalt excretion and body iron status.
Topics: Adolescent; Adult; Aged; Bone Marrow; Cobalt; Deferoxamine; Female; Ferritins; Hemosiderin; Humans; | 1975 |
Liver iron overload and desferrioxamine treatment of porphyria cutanea tarda.
Topics: Bloodletting; Chromatography, High Pressure Liquid; Chronic Disease; Deferoxamine; Ferritins; Humans | 1991 |
[The value of nuclear magnetic resonance in the study of iron overload in thalassemia patients].
Topics: Adolescent; Adult; Alanine Transaminase; Cardiomyopathies; Child; Deferoxamine; Ferritins; Hemosider | 1991 |
Use of the ferritin/alanine aspartate transaminase ratio as an iron overload marker independent of liver cell damage.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Transfusion; Combined Modality | 1989 |
Quality of life and life expectancy in thalassemic patients with complications.
Topics: Adolescent; Adult; Blood Transfusion; Child; Deferoxamine; Diabetes Mellitus, Type 1; Heart Diseases | 1989 |
Role of iron in the hydrogen peroxide-dependent oxidation of hexahydroporphyrins (porphyrinogens): a possible mechanism for the exacerbation by iron of hepatic uroporphyria.
Topics: Animals; Chick Embryo; Deferoxamine; Dose-Response Relationship, Drug; Glucose Oxidase; Hydrogen Per | 1988 |
The development of diabetes mellitus and chronic liver disease in long term chelated beta thalassaemic patients.
Topics: Adolescent; Adult; Blood Glucose; Child; Chronic Disease; Deferoxamine; Diabetes Mellitus; Female; F | 1986 |
Biliary excretion of aluminum in aluminum osteodystrophy with liver disease.
Topics: Adult; Aluminum; Aluminum Hydroxide; Bile; Bone and Bones; Bone Diseases, Metabolic; Chronic Disease | 1986 |
[Siderinuria caused by deferoxamine. II. The siderinuric increment obtained by association with ascorbic acid].
Topics: Adolescent; Adult; Aged; Anemia; Ascorbic Acid; Child, Preschool; Deferoxamine; Drug Therapy, Combin | 1973 |
[Disorders of iron metabolism in liver patients].
Topics: Adult; Anemia; Biopsy; Deferoxamine; Feces; Female; Hemochromatosis; Humans; Iron; Iron Isotopes; Li | 1966 |
[Experiences with iron elimination therapy in porphyria cutanea tarda].
Topics: Adult; Bloodletting; Deferoxamine; Female; Humans; Iron; Liver Diseases; Male; Middle Aged; Porphyri | 1971 |
[Diagnostic value of some iron metabolic parameters in acute and chronic liver diseases].
Topics: Adolescent; Adult; Aged; Autoradiography; Binding Sites; Deferoxamine; Humans; Iron; Iron Chelating | 1971 |
[Liver parenchyma damage by treatment with desferrioxamine B].
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; | 1969 |
Differential ferrioxamine test in haemochromatosis and liver diseases.
Topics: Adult; Bloodletting; Cholestasis; Deferoxamine; Diagnosis, Differential; Female; Hemochromatosis; Hu | 1969 |
[On the usefulness of iron kinetics studied with Fe59 in the differential diagnosis of idiopathic siderochromatosis and that secondary to liver diseases].
Topics: Adult; Deferoxamine; Hemochromatosis; Hemosiderosis; Humans; Iron; Iron Isotopes; Liver Diseases; Mi | 1967 |
[Iron storage disease].
Topics: Adult; Anemia; Child; Deferoxamine; Female; Hemochromatosis; Humans; Iron; Liver Diseases; Male; Mid | 1967 |
[Demonstration of increased iron storage in the organism with desferrioxamine (desferal test)].
Topics: Deferoxamine; Hemochromatosis; Hemosiderosis; Humans; Iron; Jaundice; Liver Diseases; Porphyrias | 1965 |